Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

BackgroundProgrammed cell death 1 receptor (PD-1) inhibition as monotherapy followed by Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibition in case of progression or as upfront double co-inhibition has drastically improved the survival outcomes of metastatic melanoma. Still, many patient...

Full description

Bibliographic Details
Main Authors: Georgios Lyrarakis, Michael Liontos, Amalia Anastasopoulou, Spyridon Bouros, Aikaterini Gkoufa, Panagiotis Diamantopoulos, Helen Gogas, Dimitrios C. Ziogas
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Oncology
Subjects:
lenvatinib
pembrolizumab
anti-CTLA-4
anti-PD-1
double immunotherapy
melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1420879/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1420879/full

Similar Items